Integrated serum metabolomics reveal molecular mechanism of Xietu Hemu prescription on metabolic dysfunction-associated steatotic liver disease-related obesity

Figure 3 Xietu Hemu prescription restrains lipid synthesis during the differentiation of 3T3-L1 cells. A: Schematic diagram of the differentiation process of 3T3-L1 cells by Xietu Hemu prescription (XHP)-containing serum intervention; B and C: Photos of oil red O staining of 3T3-L1 cell differentiation on day 6 and 10; D and E: Oil red O staining micro camera and statistics of difference in lipid droplet area occupation on day 10; F and G: Detection of intracellular lipid levels on day 10 (n = 3); H-K: Detection and quantitative statistics of intracellular lipid synthesis-related protein levels on day 10 (n = 3). Data were expressed as mean ± SEM. 200 ×, 50 μm; 400 ×, 25μm. ^aP < 0.01 vs model; ^bP < 0.005 vs model; ^cP < 0.001 vs model; ^dP < 0.05 vs low dose of XHP (L-XHP); ^eP < 0.01 vs L-XHP; ^fP < 0.005 vs L-XHP; ^gP < 0.001 vs L-XHP; ^hP < 0.05 vs medium dose of XHP (M-XHP); ⁱP < 0.005 vs M-XHP. XHPS: Xietu Hemu prescription-containing serum; L-XHP: Low dose of Xietu Hemu prescription; M-XHP: Medium dose of Xietu Hemu prescription; H-XHP: High dose of Xietu Hemu prescription; VehS: Vehicle serum; TC: Total cholesterol; TG: Triglyceride.